uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Potential role of transforming growth factor beta1 in drug resistance of tumor cells
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Ludwig Institute for Cancer Research.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Ludwig Institute for Cancer Research.
2003 (English)In: Acta Biochimica Polonica, ISSN 0001-527X, E-ISSN 1734-154X, Vol. 50, no 2, 497-508 p.Article in journal (Refereed) Published
Abstract [en]

Acquired drug resistance of tumor cells is frequently observed in cancer patients undergoing chemotherapy. We studied murine leukemia L1210 cells sensitive and resistant to the cytotoxic action of cisplatin and showed that cisplatin-resistant leukemia cells were also refractory to TGF beta1-dependent growth inhibition and apoptosis. Addressing the question about the mechanisms responsible for the cross-resistance to cisplatin and TGF beta1, we found that cisplatin- and TGF beta1-resistant L1210 cells possessed a decreased expression of type I TGF beta1 receptor, while the expression of type II TGF beta1 receptor was not affected. Western blot analysis of Smad proteins 2, 3, 4, 6, and 7, which participate in signal transduction pathway down-stream of the TGF beta1 receptors, revealed an increased expression of Smad 6, inhibiting TGF beta1 action, only in cisplatin- and TGF beta1-resistant L1210 cells. TGF beta1 and especially the cytotoxic mistletoe agglutinin increased Smad 6 expression in TGF beta1-sensitive but not in TGF beta1-resistant L1210 cells. TGF beta1-resistant L1210 cells also differed from TGF beta1-sensitive cells by the lack of expression of the pro-apoptotic p53 protein and higher level of expression of the anti-apoptotic Bcl-2 protein. Thus, the described co-expression of tumor cell refractoriness to an anti-cancer drug and to the inhibitory cytokine TGF beta1 is accompanied by multiple changes in the TGF beta1 signal transduction pathway and in other regulatory systems of the target cells. Besides, we found that various anti-tumor drugs and cytotoxic plant lectins increased the level of TGF beta1 expression in both TGFbeta1-sensitive and -resistant L1210 cells. A hypothesis is proposed that TGFbeta1 can at least partly mediate the effect of cell-stressing agents and, thus, the development of TGF beta1 resistance may be responsible for the appearance of tumor cell refractoriness to the action of some anti-cancer drugs.

Place, publisher, year, edition, pages
2003. Vol. 50, no 2, 497-508 p.
Keyword [en]
Animals, Antineoplastic Agents/*pharmacology, Apoptosis/drug effects, Cell Count, Cell Division/drug effects, Cell Line; Tumor, Cisplatin/*pharmacology, DNA Fragmentation/drug effects, DNA-Binding Proteins/biosynthesis, Drug Resistance; Multiple, Drug Resistance; Neoplasm, Lectins/pharmacology, Leukemia L1210/drug therapy/metabolism/pathology, Mice, Proto-Oncogene Proteins c-bcl-2/biosynthesis, Receptors; Transforming Growth Factor beta/biosynthesis, Signal Transduction, Smad Proteins, Time Factors, Trans-Activators/biosynthesis, Transforming Growth Factor beta/metabolism/*pharmacology, Transforming Growth Factor beta1, Tumor Suppressor Protein p53/biosynthesis
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-10424PubMedID: 12833174OAI: oai:DiVA.org:uu-10424DiVA: diva2:38192
Available from: 2007-03-22 Created: 2007-03-22 Last updated: 2017-12-11Bibliographically approved

Open Access in DiVA

No full text

Other links

PubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12833174&dopt=Citation

Authority records BETA

Yakymovych, MariyaSouchelnytskyi, SerhiyYakymovych, Ihor

Search in DiVA

By author/editor
Yakymovych, MariyaSouchelnytskyi, SerhiyYakymovych, Ihor
By organisation
Ludwig Institute for Cancer Research
In the same journal
Acta Biochimica Polonica
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 377 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf